AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 92 min read$CAL

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High

Caleres Inc (CAL) reported Q2 earnings of $0.47 per share, beating estimates of $0.37, and raised FY26 EPS guidance. Shares rose 14.4% to $13.76. Other companies like Opus Genetics (IRD), Signet Jewelers (SIG), and Flotek Industries (FTK) also saw significant gains due to positive updates.

Original reporting
benzinga.com
Published Sep 9, 2026, 2:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 2:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CAL
Bullish
high confidence
Mentioned
$CAL · $IRD · $SIG · $ODD · $FTK · $ASO
Relevance
8/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$CALBullishHigh
01

Why it matters

Earnings beats and guidance upgrades drove notable intraday rallies across diverse sectors.

02

Market read

Multiple earnings surprises provide short‑term trading opportunities.

03

What to watch

Potential supply‑chain constraints for retail firms could temper upside.

Relevance 8/10Novelty 8/10Timing: same-day earnings surprise

Background

Market opened lower overall, but several stocks posted strong earnings-driven gains.

Company-level read

Ticker impact

$CALBullishHigh confidence
Context

Caleres reported Q2 earnings beat and raised FY26 EPS guidance, shares jumped 14.4%.

Expected impact

Potential continued rally; consider buying on pullback.

Evidence & confidence

Double‑digit price move on fresh earnings data indicates fresh buying pressure.

$IRDBullishHigh confidence
Context

Opus Genetics announced positive Phase 1/2 trial results, shares surged 61.6%.

Expected impact

Short‑term upside expected; monitor for further data releases.

Evidence & confidence

Biotech trial news drives large intraday move.

$SIGBullishMedium confidence
Context

Signet Jewelers posted better‑than‑expected Q2 earnings and raised FY27 EPS guidance, shares up 19%.

Expected impact

Likely continued strength; consider long position.

Evidence & confidence

Strong earnings surprise with sizable move.

$ODDBullishMedium confidence
Context

Oddity Tech delivered better‑than‑expected Q2 results and raised FY26 sales guidance, shares up 16.7%.

Expected impact

Potential upside; watch for follow‑up guidance.

Evidence & confidence

Guidance improvement drives price move.

$FTKBullishMedium confidence
Context

Flotek Industries raised its 2026 guidance, shares surged 12.4%.

Expected impact

Short‑term rally likely.

Evidence & confidence

Guidance lift aligns with price jump.

$ASOBullishMedium confidence
Context

Academy Sports reported better‑than‑expected Q2 adjusted EPS and raised FY26 guidance, shares up 11.7%.

Expected impact

Potential continued upside.

Evidence & confidence

Strong earnings data drives move.

$FSLYBullishLow confidence
Context

Fastly rose 10.9% after market, implied positive sentiment.

Expected impact

Monitor for continuation.

Evidence & confidence

No specific catalyst disclosed.

$AMBABullishLow confidence
Context

Ambarella gained 10.7% on the day.

Expected impact

Short‑term upside possible.

Evidence & confidence

No concrete news cited.

Market effects

Sector

Retail and biotech earnings beats lift sector sentiment.

Regional

U.S. equities gain from multiple earnings surprises.

Global

Limited to U.S. listed companies; no broader macro impact.

Counterpoint

What could challenge this read

Some price jumps may be overbought; consider profit‑taking on short‑term rallies.

Key entities

  • Company
    Caleres

    Footwear retailer reporting Q2 earnings beat.

  • Company
    Opus Genetics

    Biotech firm announcing positive trial data.

Read at source← All news

Related articles

OCT 23
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat, showing strong efficacy in pancreatic and lung cancers when combined with Revolution Medicines' (RVMD) RAS(ON) inhibitors. The combination achieved 82% and 80% response rates in pancreatic and lung cancer patients, respectively. Tango plans a global registrational study in 2027. TNGX shares fell 10.65% to $24.95 on Friday.

finance.yahoo.com2 min